The oxidation of plasma LDLs (low-density lipoproteins) is a key event in the pathogenesis of atherosclerosis. LPC (lysophosphatidylcholine) and oxysterols are major lipid constitutents of oxidized LDLs. In particular, 7-oxocholesterol has been found in plasma from cardiac patients and atherosclerotic plaque. In the present study, we investigated the ability of 7-oxocholesterol and LPC to regulate the activation of eNOS (endothelial nitric oxide synthase) and cPLA 2 (cytosolic phospholipase A 2 ) that synthesize two essential factors for vascular wall integrity, NO (nitric oxide) and arachidonic acid. In endothelial cells from human umbilical vein cords, both 7-oxocholesterol (150 µM) and LPC (20 µM) decreased histamine-induced NO release, but not the release activated by thapsigargin. The two lipids decreased NO release through a PI3K (phosphoinositide 3-kinase)-dependent pathway, and decreased eNOS phosphorylation. Their mechanisms of action were, however, different. The NO release reduction was dependent on superoxide anions in LPC-treated cells and not in 7-oxocholesterol-treated ones. The Ca 2+ signals induced by histamine were abolished by LPC, but not by 7-oxocholesterol. The oxysterol also inhibited (i) the histamine-and thapsigargininduced arachidonic acid release, and (ii) the phosphorylation of both cPLA 2 and ERK1/2 (extracellular-signal-regulated kinases 1/2). The results show that 7-oxocholesterol inhibits eNOS and cPLA 2 activation by altering a Ca 2+ -independent upstream step of PI3K and ERK1/2 cascades, whereas LPC desensitizes eNOS by interfering with receptor-activated signalling pathways. This suggests that 7-oxocholesterol and LPC generate signals which cross-talk with heterologous receptors, effects which could appear at early stage of atherosclerosis.
INTRODUCTION
Endothelial dysfunction represents a key early step in the development of atherosclerosis and is responsible for plaque progression and atherosclerotic complications [1] . Endothelial dysfunction is characterized by an imbalance between relaxing and contracting factors, pro-coagulant and anti-coagulant substances, and between pro-inflammatory and anti-inflammatory mediators [2] . Nitric oxide (NO) is a potent vasodilator essential in the maintenance of vascular wall integrity. It is synthesized from L-arginine by NOS (NO synthase) and it inhibits platelet aggregation and adhesion, leucocyte migration and adhesion, and smooth muscle cells migration and proliferation [3, 4] . In addition, NO plays a fundamental role in the development of atherosclerosis by stimulating or inhibiting lipid peroxidation reactions and lipid or lipoprotein oxidation, according to the underlying oxidative status of the vascular tissue [5, 6] . Peroxidation of membrane lipids affects the activity of the cPLA 2 (cytosolic phospholipase A 2 ) that releases arachidonic acid by hydrolysing phospholipids [7] . Arachidonic acid is the precursor of eicosanoids, especially prostacyclin and thromboxane A 2 that exert opposite action on vascular tone and platelet aggregation [8] .
Clinical studies have shown that the elevation of plasma LDLs (low-density lipoproteins) and their oxidation are associated with impairment of endothelium-mediated vasodilation Abbreviations used: BHT, butylated hydroxytoluene; [Ca 2+ ] i , cytosolic Ca 2+ concentration; cPLA 2 , cytosolic phospholipase A 2 ; ERK1/2, extracellularsignal-regulated kinases 1/2; GPCR, G-protein-coupled receptor; HUVEC, human umbilical vein endothelial cell; LDL, low-density lipoprotein; LPC, lysophosphatidylcholine; MEK, MAPK/ERK kinase; NOS, nitric oxide synthase; eNOS, endothelial NOS; OSBP, oxysterol-binding protein; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; p38 MAPK, p38 mitogen-activated protein kinase. 1 To whom correspondence should be addressed (e-mail monique.dufilho@brs.ap-hop-paris.fr).
in the earliest stage of atherosclerosis [9, 10] . Oxidation of LDL result in extensive conversion of phosphatidylcholine to LPC (lysophosphatidylcholine) and formation of cholesteryl ester core aldehydes, which are further converted into free-and apolipoprotein-B-bound oxysterols, and, in particular, 7-oxocholesterol [11, 12] . Although it is well documented that LPC has inflammatory activities and activates signalling molecules, such as Ca 2+ , arachidonic acid or tyrosine kinases [13] [14] [15] , the specific cell-surface receptor by which it mediates signals at the vessel wall has not yet been clearly characterized in endothelial cells. In addition to LPC, oxysterols may also contribute to the development of atherosclerosis [16] . Increased plasma levels of β-epoxycholesterol and 7-oxygenated oxysterols have been observed in patients with coronary artery diseases [17, 18] .
In a previous study, we demonstrated that cholesterol derivatives oxidized at the 7 position reduce agonist-activated NO release in human endothelial cells [19] . In the present study, we investigated the ability of 7-oxocholesterol and LPC to regulate the signalling pathways involved in eNOS (endothelial NOS) and cPLA 2 activation. The results suggest that 7-oxocholesterol inhibits eNOS and cPLA 2 activation by altering a Ca 2+ -independent step upstream of PI3K (phosphoinositide 3-kinase) and ERK1/2 (extracellular-signal-regulated kinases 1/2) cascades, whereas LPC desensitizes eNOS by interfering with the signalling pathways activated by histamine.
EXPERIMENTAL

Materials
Culture medium and products were purchased from Invitrogen (Cergy-Pontoise, France). fura-2/AM (fura 2 acetoxymethyl ester) was obtained from Molecular Probes (Eugene, OR, U.S.A.). The polyclonal antibodies against phospho-Ser 1177 -eNOS, phosphoSer 505 -cPLA 2 , phospho-ERK1/2, phospho-p38 MAPK (p38 mitogen-activated protein kinase) and p38 MAPK, and monoclonal antibody against ERK1/2, were from Cell Signaling Technology (Beverly, MA, U.S.A.). The monoclonal antibodies against eNOS and cPLA 2 were from BD Transduction Laboratory (Heidelberg, Germany) and Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.) respectively. The [1- 14 C]arachidonic acid was obtained from PerkinElmer (Boston, MA, U.S.A.). All other products were purchased from Sigma-Aldrich Chimie (St Quentin Fallavier, France) or Bio-Rad Laboratories (Hercules, CA, U.S.A.).
LDL was isolated by sequential ultracentrifugation from fresh citrated plasma from normolipidaemic donors, and the oxidative modification of LDL was performed as described previously [20] . Briefly, 1.2 mg of protein/ml LDL was incubated for 24 h at 37
• C in PBS containing 5 µM CuSO 4 , and oxidation was stopped by adding 200 µM EDTA and 20 µM BHT (butylated hydroxytoluene). Native LDL was maintained for 24 h at 4
• C in PBS containing EDTA and BHT. Both native and oxidized LDL were dialysed overnight against PBS. The samples we used contained 158 and 38 µg/ml LPC, 8.62 and 1.28 µg/ ml 7α-hydroxycholesterol, 20.43 and 1.39 µg/ml 7β-hydroxycholesterol, and 173 and 2.6 µg/ml 7-oxocholesterol for oxidized and native LDL respectively.
Cell culture and treatments
Endothelial cells were isolated from segments of human umbilical cord vein by collagenase digestion. HUVECs (human umbilical vein endothelial cells) were cultured in medium 199 (40 %) and RPMI 1640 (40 %) supplemented with 20 % fetal calf serum as described previously [21] . At confluence (4-5 days), cells were detached by incubation for 1-2 min at 22
• C with 0.01 % trypsin and 0.004 % EDTA, washed and grown until subconfluence to be used at the first passage. HUVECs were cultured on to glass coverslips (9 mm × 35 mm) for [Ca 2+ ] i (cytosolic Ca 2+ concentration) determinations, or on to 35-or 60-mm plastic culture dishes for NO, arachidonic acid measurements or Western blot analysis. Three different cell treatments were performed: (1) incubation for 2 h at 37
• C in culture medium with either 50 µg of protein/ml native or oxidized LDL or with 155 µM (60 µg/ml) cholesterol and 20 µM BHT to prevent cholesterol oxidation [19] or with 150 µM (60 µg/ml) 7-oxocholesterol (50 mM stock solutions in ethanol); (2) incubation for 15 min at 37
• C in respective reaction buffers with 20 µM LPC (20 mM stock solution in ethanol); (3) incubation for 30 min in culture medium in the dark with inhibitors PD98059 or LY294002 (20 µM stock solution in DMSO). After treatment, cells were washed and then incubated in the respective reaction buffers. The amount of proteins per dish, measured as described previously [22] , was not altered by the treatment. [21] . Fluorescence intensities were recorded on a spectrofluorimeter SPEX CMIII (ISA-Jobin-Yvon, Longjumeau, France). Each measurement was systematically corrected for autofluorescence of unloaded cells and the calibration parameters of fura-2 signals were determined as described previously [21] .
Measurements of NO
Cells were incubated for 15 min at 37
• C in PBS containing 5 mM glucose, 0.5 mM MgCl 2 and 1 mM CaCl 2 (PBS-MgCa). NO concentration was measured at the surface of HUVECs by differential pulse amperometry with a three-electrode potentiostatic Biopulse system (Tacussel-Radiometer, Lyon, France) and a porphyrinic NO-selective microsensor, as described previously [23] . NO sensor was calibrated at both the beginning and the end of measurements in the presence of cells, by the addition of NO standard solutions as described previously [24] . The calibration curves were similar for control and treated cells. The electrode sensitivity was 1.5 + − 0.2 pA/nM NO (n = 17). NO release was determined as the maximum of the agonist-induced oxidation current.
Quantification of arachidonic acid release
Arachidonic acid release, that reflects cPLA 2 activation under our experimental conditions, was determined as reported previously [22] . HUVECs labelled for 20 h with 0.06 µCi of [1- 14 C] arachidonic acid were washed, treated with cholesterol or 7-oxocholesterol, and then stimulated by histamine or thapsigargin for 10 min in PBS-MgCa. Cholesterol, 7-oxocholesterol or kinase inhibitors did not modify arachidonic acid release in unstimulated cells.
Immunoblotting
Cells, incubated in PBS-MgCa, were washed and harvested in ice-cold buffer containing 150 mM sodium chloride, 50 mM Tris, 1 mM EDTA, 50 mM NaF, 1 mM sodium orthovanadate, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml pepstatin and 1 % (v/v) Nonidet P-40. The lysates were cleared by centrifugation at 12 000 g for 15 min at 4
• C. The different samples containing equal amounts of protein were resolved by SDS/PAGE (8 % gel). The separated proteins were transferred electrophoretically on to nitrocellulose membranes and nonspecific binding sites were blocked in Tris-buffered saline containing 0.1 % Tween 20 and 5 % non-fat dried milk. Membranes were incubated overnight with primary antibodies against phospho-ERK, -p38 MAPK, -cPLA2 or -eNOS, or against corresponding non-phosphorylated enzymes. The washed membranes were then incubated with horseradish-peroxidase-conjugated secondary antibody. The immunoreactive bands were detected by an enhanced chemiluminescence system and quantified by densitometry using National Institutes of Health Image 1.61 software.
Statistical analysis
Results are expressed as the means + − S.E.M. for n independent experiments. Multiple comparisons and time-dependent effect were examined by one-way analysis of variance with post hoc Fisher's test, with P < 0.05 considered as statistically significant. 
RESULTS
Effects of LDL and its lipid constituents on NO and arachidonic acid release
The stimulation of HUVECs by histamine, an agonist of the GPCR (G-protein-coupled receptor) H 1 , or by thapsigargin, a selective inhibitor of endoplasmic reticulum Ca 2+ -ATPase, activated both NO and arachidonic acid release (Figure 1 ). Histamine induced a transient NO production that progressively returned to basal levels ( Figure 1A) . The cell treatment with 7-oxocholesterol or LPC inhibited the histamine-induced NO release by 36 + − 4 or 50 + − 7 % respectively (n = 6, P < 0.001 or P < 0.01 respectively), whereas that with cholesterol had no effect (95 + − 14 %) ( Figure 1A) . Similarly, oxidized LDL decreased NO release by 44 + − 12 %, whereas native LDL had no effect ( Figure 1B ). In contrast with histamine, thapsigargin progressively increased the NO concentrations to a plateau that remained stable during 3-4 min. Cholesterol, 7-oxocholesterol or LPC treatment did not affect the thapsigargin-activated NO release ( Figures 1C and 1D ). The result indicates that both 7-oxocholesterol and LPC require the receptor-dependent activation of eNOS to reduce NO release.
Histamine and thapsigargin also activated cPLA 2 , leading to arachidonic acid release ( Figures 1E and 1F ). As expected, pretreatment of HUVECs by cholesterol had no effect on the arachidonic acid release, whereas 7-oxocholesterol was a strong inhibitor (over 63 % inhibition). The LPC effects were not studied, since it has been previously demonstrated that this phospholipid activates the arachidonic acid release [14] . Native and oxidized LDLs induced non-significant increases in arachidonic acid release in histamine-(25 + − 18 and 24 + − 16 % respectively) and thapsigargin-stimulated cells (35 + − 18 and 29 + − 15 % respectively). Of note, 7-oxocholesterol alone inhibited the arachidonic acid release, although LDLs tend to increase the arachidonic acid release.
It is generally admitted that oxidation of LDLs results in a decreased NO availability by increasing O 2 − (superoxide anions) production. In order to examine the participation of extracellular O 2 − in the 7-oxocholesterol and LPC effects, HUVECs were stimulated by histamine in the presence of superoxide dismutase to scavenge O 2 − . In the presence of 200 units/ml superoxide dismutase, the inhibition of NO release by 7-oxocholesterol was maintained (10 + − 1 versus 23 + − 3 nM in control, n = 6), whereas that by LPC was suppressed (26 + − 5 versus 23 + − 3 nM, n = 6). These results show that the two major lipid constituents of oxidized LDL act differently, since the LPC effect was dependent of extracellular O 2 − , not that of 7-oxocholesterol.
7-Oxocholesterol and LPC effects on Ca 2+ signals and eNOS phosphorylation
To study further the different signalling pathways which LPC and 7-oxocholesterol could effect, we studied eNOS activation. eNOS is activated by intracellular Ca 2+ signals and by phosphorylation cascades. Histamine induced a transient phosphorylation of Ser 1177 on eNOS and a biphasic Ca 2+ signal (Figure 2 ). The eNOS phosphorylation was maximal between 1 and 2 min, and progressively returned to basal levels within 20 min. (Figure 2A ). The Ca 2+ peak, corresponding to Ca 2+ mobilization from internal stores, is reached 30 s after histamine addition and is followed by a sustained plateau reflecting Ca 2+ entry from the extracellular ] i from 117 + − 15 nM to 177 + − 18 nM and 243 + − 47 nM (P < 0.05 and P < 0.01) respectively. However, the two lipids altered the Ca 2+ response to histamine differently. The Ca 2+ signals was increased by 86 + − 22 % by 7-oxocholesterol, whereas they were totally inhibited by LPC ( Figure 2B ). In contrast, both lipids reduced the histamine-induced eNOS phosphorylation ( Figure 2C ). The results suggest that 7-oxocholesterol decreases NO release by inhibiting the eNOS phosphorylation through a Ca 2+ -independent mechanism, whereas LPC inhibits both Ca 2+ signals and eNOS phosphorylation.
Since eNOS is phosphorylated independently of Ca 2+ through the PI3K-Akt pathway [25] , we studied the effect of the PI3K inhibitor, LY294002. The latter dose dependently inhibited the histamine-activated NO release with a biphasic effect of an apparent IC 50 of 0.1 µM and 80 % reduction at 20 µM ( Figure 3A) . From 50 nM to 50 µM, however, LY294002 reduced the histamine-induced eNOS phosphorylation at Ser 1177 by only 30 % (Figure 3B ), indicating that other residues than Ser 1177 were phosphorylated on eNOS through the PI3K cascade. Cell treatment by LY294002 following that with 7-oxocholesterol or preceding that with LPC did not further decrease the NO release ( Figure 3C) . Furthermore, the histamine-activated NO release did not depend on ERK1/2 pathways, since the MEK1/2 (MAPK kinase) inhibitor PD98059 (from 5 to 50 µM) had no effect on it (16 + − 3 versus 14 + − 2 nM in control cells, n = 5). Altogether the results suggest that the two lipids alter the PI3K-dependent eNOS activation. Phosphorylation was measured in histamine-stimulated HUVECs by Western-blot analysis using antibodies directed against phospho-ERKs (p-ERK1/2), -p38 MAPK (p-p38) or -Ser 505 cPLA 2 (p-cPLA 2 ). Levels of ERK1/2, p38 MAPK or cPLA 2 were assessed using antibodies against the non-phosphorylated forms. (A) Time course of ERK1/2, p38 MAPK or cPLA 2 phosphorylation in 10 µM histamine-stimulated HUVECs. Densitometric data are expressed as the means + − S.E.M. for 3 independent experiments. (B) Effects of 7-oxocholesterol on ERK1/2, p38 MAPK or cPLA 2 phosphorylation in HUVECs pretreated for 2 h with either vehicle (control) or 150 µM 7-oxocholesterol (7-keto) and stimulated for 10 min by 10 µM histamine. Densitometric data are expressed as the means + − S.E.M. for 3-7 independent experiments. *P < 0.05 compared with control cells.
7-Oxocholesterol effects on ERK1/2 and cPLA 2 phosphorylation
We have investigated the ability of 7-oxocholesterol to regulate the kinase pathways involved in the cPLA 2 activation, the ERK1/2 and p38 MAPK cascades. As shown in Figure 4 (A), histamine activated the phosphorylation of ERK1/2 (left-hand panel), p38 MAPK (middle panel) and cPLA 2 (right-hand panel) with similar time courses. Phosphorylation was maximal at 10 min. Cell treatment by 7-oxocholesterol inhibited histamine-induced phosphorylation of ERK1/2 and cPLA 2 by 27 + − 5 and 33 + − 13 % respectively. In contrast, it had no effect on phospho-p38 MAPK ( Figure 4B ). Figure 5 (A) shows that thapsigargin, which acts independently of a receptor, activated the phosphorylation of ERK1/2 (lefthand panel), p38 MAPK (middle panel) and cPLA 2 (right-hand panel). The phosphorylation of ERK1/2 and cPLA 2 was intense and maximal at 10 min, and phosphorylation of p38 MAPK was slow and weak. The 7-oxocholesterol treatment resulted in 40 % decrease in ERK1/2 and cPLA 2 phosphorylation, but had no effect on that of p38 MAPK ( Figure 5B ), indicating that the oxysterol decreases the cPLA 2 activity by inhibiting the ERK1/2 phosphorylation. Thapsigargin induced a progressive [Ca 2+ ] i increase which remained stable over several minutes ( Figure 5C ). The 7-oxocholesterol treatment suppressed the thapsigargininduced Ca 2+ signals. To investigate whether the inhibitory effect of 7-oxocholesterol on ERK1/2 phosphorylation was direct or occurred at an upstream step, we used the MEK inhibitor PD98059. The inhibitor inhibited dose-dependently the ERK1/2 phosphorylation activated by histamine and thapsigargin with a total inhibition at 10 µM (Figure 6A, left-hand panels) . At this concentration, PD98059 reduced the phosphorylation of cPLA 2 in histamine-and thapsigargin-stimulated HUVECs by only 34 + − 2 and 26 + − 13 % respectively ( Figure 6A, right-hand panels) . In accordance with this observation, PD98059 inhibited the histamine-and thapsigargininduced arachidonic release by 40 + − 5 and 35 + − 5 % respectively ( Figure 6B) . Interestingly, the 7-oxocholesterol inhibitory effect was greater than that of PD98059 (61 versus 40 % and 64 versus 35 % in histamine-and thapsigargin-activated cells respectively). Addition of PD98059 following 7-oxocholesterol treatment did not decrease further the histamine-or thapsigargin-induced arachidonic acid release. However, the effects of 7-oxocholesterol and PD98059 were not cumulative. Furthermore, histamine and thapsigargin activated arachidonic acid release independently of the PI3K cascade, since the PI3K inhibitor LY294002, even at the high concentration of 20 µM, had no effect (14.0 + − 2.5 versus 17.7 + − 3.5 and 18.1 + − 0.1 versus 19.7 + − 6.6 10 3 d.p.m./mg of protein respectively). The results show that the 7-oxocholesterol inhibits cPLA 2 activity through the ERK1/2 signalling pathway.
DISCUSSION
The membrane eNOS and the cPLA 2 are two essential enzymes for endothelial function, and in particular the regulation of vascular tone, homoeostasis and integrity. The present study shows that two major constituents of oxidized LDL, LPC and 7-oxocholesterol, reduced NO and arachidonic acid release, and did so through distinct mechanisms of action. LPC desensitizes eNOS by interfering with the signalling pathways of the histamine receptor. The cholesterol oxide, 7-oxocholesterol, inhibits eNOS and cPLA 2 activity by altering the PI3K-and ERK1/2-dependent phosphorylation respectively.
The eNOS activation by GPCR agonists depends on calmodulin and Ca 2+ and on phosphorylation/dephosphorylation events that control calmodulin binding to the enzyme and the flow of electrons for NADPH oxidation [25] . The kinase cascades involved in the above processes depend on the stimulus applied; eNOS is phosphorylated either by protein kinase A, protein kinase B, AMP-activated protein kinase or PKC (protein kinase C). The cPLA 2 activation following a GPCR stimulation depends on Ca signal, phosphorylation by ERK1/2 and p38 MAPK, and translocation from cytosol to either the perinuclear region, including the nuclear envelope, the Golgi apparatus and the endoplasmic endothelium or the plasma membrane [26, 27] .
In the present study, the LPC treatment of HUVECs increases the basal [Ca 2+ ] i values and suppresses the Ca 2+ response to histamine. This agrees with previous studies demonstrating that LPC induced Ca 2+ signals in a phospholipase C-dependent manner [28] , and that basal [Ca 2+ ] i values did not return to their initial levels after LPC removing [13] . Indeed, LPC activates Ca 2+ signals through the GPCR GPR4 [29] , which is expressed in human endothelial cells [30] . Through its binding to GPR4, LPC may desensitize the Ca 2+ response to histamine. In rabbit aorta, LPC inhibited the acetylcholine-induced Ca 2+ signals and endothelium-dependent relaxation [31] . In the present study, LPC had no effect on the receptor-independent activation of NO release induced by thapsigargin, but reduced the histamine-activated NO release through a mechanism dependent on extracellular O 2 − . It has been demonstrated that LPC activated O 2 − synthesis by NAD(P)H oxidase [32] and elicited NO-dependent cGMP release [33] . The O 2 − is rapidly dismutated to H 2 O 2 , which has been shown to activate both NO synthesis and phosphorylation of Ser 1177 on eNOS through a Ca 2+ -and PI3K-sensitive pathway [34] . We observed that LPC decreased the level of phosphorylated Ser 1177 on eNOS and reduced NO release through a PI3K-dependent pathway. LPC could inhibit the histamine-induced eNOS activation by eliciting enzyme desensitization and/or its translocation from plasma membrane to perinuclear region.
Various GPCR agonists, indeed, induced the eNOS translocation [35, 36] .
The cholesterol oxide 7-oxocholesterol reduced the histamineinduced NO release through a mechanism different from that of LPC, since its effect was independent of extracellular O 2 − . These results are in agreement with previous observations relating an impairment of endothelium-dependent relaxation by 7-oxocholesterol independently of extracellular O 2 − [37] . It has been recently demonstrated that 7-oxocholesterol accumulates preferentially in lipid rafts of the plasma membrane and decreases their cholesterol content [38] . Caveolin-1, a structural protein of the lipid raft caveolae, negatively regulates eNOS activity [39] . 7-Oxocholesterol may reduce the NO release by disturbing the local environment of eNOS in caveolae, which is involved in intracellular cholesterol transport. We observed that cholesterol had no effect on [ 2+ signals, but had no effect on NO release. This strengthens our previous observation that 7-oxocholesterol did not alter the receptor-independent NO synthesis [19] , and supports the proposal that it inhibited eNOS and cPLA 2 activity through Ca 2+ -independent mechanisms. The inhibition of NO and arachidonic acid release by 7-oxocholesterol was associated with a decreased phosphorylation of Ser 1177 on eNOS and Ser 505 on cPLA 2 . The fact that the oxysterol inhibited only the histamine-induced NO production, while it decreased both receptor-dependent and -independent arachidonic acid release, could be due to the different localization of eNOS and cPLA 2 and to the different kinase cascades involved in their activation. Phosphorylation of eNOS at Ser 1177 is down-regulated by PKC signalling, which attenuates the eNOS activation [40] . Interestingly, 7-oxocholesterol does increase PKC activity [37] . In the present study, 7-oxocholesterol, by increasing the cytosolic Ca 2+ , may activate a Ca 2+ -dependent PKC isoform that would prevent the phosphorylation of Ser 1177 on eNOS by histamine. The participation of PI3K in the eNOS activation was indicated by the reduction of eNOS phosphorylation and the strong inhibition of NO release elicited by the PI3K inhibitor LY294002. The effects of the latter were, however, annihilated in 7-oxocholesterol-treated cells, suggesting that the oxysterol and the PI3K inhibitor act on a common target. The phosphorylation of caveolin-2, which activates the caveolin-1-dependent formation of caveolae, was also inhibited by LY294002 [41] . 7-Oxocholesterol could inhibit eNOS phosphorylation by altering the caveolar structure.
Histamine and thapsigargin phosphorylated cPLA 2 , ERK1/2 and p38 MAPK with similar time courses as we have described previously for arachidonic acid release [22] . This agrees with previous studies demonstrating the stimulation of ERK1/2 by histamine in HUVECs [42, 43] . Interestingly, 7-oxocholesterol decreased the phosphorylation of cPLA 2 and ERK1/2, but did not modify that of p38 MAPK in both histamine-and thapsigargintreated cells. However, at a concentration that abolished the ERK1/2 phosphorylation, the MEK inhibitor PD98059, had a less marked inhibitory effect than 7-oxocholesterol on arachidonic acid release. The oxysterol may prevent the full activation of cPLA 2 by histamine or thapsigargin by modulating upstream steps of ERK1/2 cascade. In HUVECs, the association of Ca 2+ -independent PKCδ with the upstream activator of MEK, Raf-1, controlled the ERK1/2 activation [44] . Through the activation of a Ca 2+ -dependent PKC isoform, 7-oxocholesterol could downregulate the Raf-MEK pathway by involving another PKC isoform. OSBP (oxysterol-binding protein) is a cytosolic receptor for different oxysterols, including 7-oxocholesterol, that interacts with proteins involved in cellular signalling processes and, in particular, the anchoring protein of PKC [45] . 7-Oxocholesterol could mediate its effects on ERK1/2 cascade through binding to OSBP, but the expression of this protein remains to be demonstrated in human endothelial cells.
Our present study highlights a modulation by two oxidized LDL constituents of the signalling events activating eNOS. The enzyme desensitization by LPC and the potentiation of Ca 2+ signalling by 7-oxocholesterol could be explained by the new concepts of cross-talk or transactivation/transinactivation between heterologous receptors [46, 47] . These findings obtained in vitro provide new insights on the regulation mechanisms of eNOS and cPLA 2 , which may participate in endothelial dysfunction in the early stage of atherosclerosis.
